Canaccord Genuity reduced its rating on InterMune ITMN from Buy to Hold and reduced its price target from $15 to $10 on Lower Esbriet EU Prospects.
Canaccord Genuity commented, "Lowering rating to HOLD, target to $11 on lower EU Esbriet (pirfenidone) sales prospects. Esbriet is ITMN's drug for idiopathic pulmonary fibrosis (IPF), an orphan lung disease. We still see good Esbriet EU potential (despite price concerns) and encouraging 2012 adoption. Our worldwide peak sales estimate is $1.97B in 2025."
InterMune closed at $9.90 on Monday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in